Toxic dermatosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:293815
Who is this for?
Show terms as
3Active trials40Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Toxic dermatosis is a broad term used to describe skin conditions that develop as a reaction to toxic substances. These substances can include medications, chemicals, environmental toxins, or other agents that trigger harmful reactions in the skin. The condition can range from mild rashes and redness to severe blistering, peeling, and widespread skin damage. Symptoms often include skin redness, itching, burning, swelling, blistering, and in severe cases, large areas of skin may peel away. The severity depends on the type of toxic agent involved, the amount of exposure, and the individual's sensitivity. Toxic dermatoses can affect people of any age and may appear suddenly after exposure to the offending substance. Some forms, such as drug-induced toxic skin reactions, can be life-threatening and require urgent medical attention. Treatment focuses on identifying and removing the causative agent, managing symptoms with topical or systemic medications, and providing supportive care. In severe cases, hospitalization may be needed for wound care, fluid management, and prevention of infection. Early recognition and prompt treatment are essential for the best outcomes. The treatment landscape includes corticosteroids, antihistamines, immunosuppressive agents, and supportive wound care depending on the severity and type of reaction.

Key symptoms:

Skin redness or rashItching or burning sensation on the skinBlistering of the skinPeeling or shedding of skinSwelling of affected areasPain or tenderness of the skinSkin discolorationOpen sores or ulcers on the skinFeverFeeling generally unwell or fatiguedSensitivity to touch on affected skinDry or cracked skinOozing or weeping from skin lesions

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Aug 2026Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING
Apr 2026Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening

Region Jönköping County

TrialNOT YET RECRUITING
Apr 2026Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer

Poitiers University Hospital — PHASE4

TrialNOT YET RECRUITING
Mar 2026Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

Sligo General Hospital — NA

TrialNOT YET RECRUITING
Feb 2026Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

SOLTI Breast Cancer Research Group — PHASE2

TrialRECRUITING
Feb 2026Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients

Dena h. Al-Tameemi — NA

TrialNOT YET RECRUITING
Feb 2026Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients

Shiraz University of Medical Sciences — PHASE4

TrialNOT YET RECRUITING
Jan 2026HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness

Haiphong University of Medicine and Pharmacy — PHASE4

TrialNOT YET RECRUITING
Jan 2026Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support

Universidad de Granada — NA

TrialNOT YET RECRUITING
Oct 2025Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Institut Claudius Regaud — PHASE4

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Toxic dermatosis.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Phase 3
Actively Recruiting
PI: Antonios Valachis, Assoc Prof (Region Örebro län) · Sites: Helsinki; Athens +10 more · Age: 7099 yrs
Phase 21 trial
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
Phase 2
Active
PI: Paris Kosmidis (CareAcross) · Sites: Athens; Barcelona +3 more · Age: 1899 yrs
N/A1 trial
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
N/A
Actively Recruiting
PI: Jennifer J Hu, PhD (U. of Miami) · Sites: Miami, Florida · Age: 1899 yrs

Specialists

Showing 25 of 40View all specialists →
MM
Marina Guenzi, MD
Specialist
PI on 1 active trial
DM
Daneng Li, MD
DUARTE, CA
Specialist
PI on 2 active trials
JW
Jeffrey Weber
Specialist
PI on 4 active trials62 Toxic dermatosis publications
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
DM
David S Schrump, M.D.
BETHESDA, MD
Specialist
PI on 19 active trials
SM
Shivaani Kummar, MD
PORTLAND, OR
Specialist
PI on 5 active trials
SM
Steven Rosenberg, M.D.
Specialist
PI on 4 active trials
MP
Marie-Elise TRUCHETET, MD, PhD
Specialist
PI on 3 active trials
MM
Mario Lacouture, MD
NEW YORK, NY
Specialist
PI on 3 active trials
HM
Hope S. Rugo, MD
SAN FRANCISCO, CA
Specialist
PI on 5 active trials
VS
Vincent SIBAUD
Specialist
PI on 1 active trial1 Toxic dermatosis publication
DM
David PASQUIER, MD
Specialist
PI on 1 active trial
BM
Budhi S Yadav, MD
Specialist
PI on 1 active trial
NM
Nuo Shi, MPH
Specialist
PI on 1 active trial
XP
Xiaobin Lai Dr, PhD
Specialist
PI on 1 active trial
PC
Pippa Corrie
Specialist
PI on 2 active trials
RM
Rachel Freedman, MD, MPH
Specialist
PI on 2 active trials
MB
Maryam Buni
HOUSTON, TX
Specialist
PI on 1 active trial1 Toxic dermatosis publication
JM
Jaroslaw Hepel, MD
TOWSON, MD
Specialist
PI on 1 active trial
HM
Howard S. Hochster, MD
NEW HAVEN, CT
Specialist
PI on 5 active trials
BM
Bonnie Ky, MD, MSCE
PHILADELPHIA, PA
Specialist
PI on 5 active trials
AM
Ana Oaknin, MD
Specialist
PI on 1 active trial1 Toxic dermatosis publication
EM
Evan J Lipson, M.D.
BALTIMORE, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
⚗️ Trial Site

Erasmus Medical Center

📍 Rotterdam

👤 Robert Rissmann, Professor

⚗️ Trial Site

Leiden University Medical Center

📍 Leiden

👤 Robert Rissmann, Professor

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to Toxic dermatosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Toxic dermatosisForum →

No community posts yet. Be the first to share your experience with Toxic dermatosis.

Start the conversation →

Latest news about Toxic dermatosis

Disease timeline:

New recruiting trial: Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

A new clinical trial is recruiting patients for Toxic dermatosis

New recruiting trial: Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction

A new clinical trial is recruiting patients for Toxic dermatosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the most likely cause of my skin reaction?,How can we confirm which substance triggered this reaction?,What treatments are available for my level of severity?,Are there medications or substances I need to avoid in the future?,What warning signs should prompt me to seek emergency care?,Will my skin fully recover, or should I expect lasting changes?,Should I carry a medical alert card or bracelet listing my trigger?

Common questions about Toxic dermatosis

What is Toxic dermatosis?

Toxic dermatosis is a broad term used to describe skin conditions that develop as a reaction to toxic substances. These substances can include medications, chemicals, environmental toxins, or other agents that trigger harmful reactions in the skin. The condition can range from mild rashes and redness to severe blistering, peeling, and widespread skin damage. Symptoms often include skin redness, itching, burning, swelling, blistering, and in severe cases, large areas of skin may peel away. The severity depends on the type of toxic agent involved, the amount of exposure, and the individual's sen

Are there clinical trials for Toxic dermatosis?

Yes — 3 recruiting clinical trials are currently listed for Toxic dermatosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Toxic dermatosis?

25 specialists and care centers treating Toxic dermatosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.